Status:
COMPLETED
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Childhood Acute Lymphoblastic Leukemia
Childhood Rhabdomyosarcoma
Eligibility:
All Genders
Up to 16 years
Brief Summary
This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer m...
Detailed Description
PRIMARY OBJECTIVES: I. To characterize the pharmacokinetics (PKs) of dactinomycin in infants, children, and adolescents with cancer. II. To identify demographic or physiological factors that are det...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of cancer, including, but not limited to, any of the following:
- Acute lymphoblastic leukemia
- Ewing sarcoma
- Rhabdomyosarcoma
- Soft tissue sarcoma
- Wilms tumor
- Due to receive or receiving dactinomycin and/or vincristine as a component of cancer treatment on another clinical trial
- Able to comply with study requirements
- Other concurrent chemotherapeutic agents allowed
Exclusion
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT00674193
Start Date
February 1 2008
Last Update
May 17 2017
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Miller Children's Hospital
Long Beach, California, United States, 90806
3
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
4
Childrens Hospital of Orange County
Orange, California, United States, 92868-3874